# Mediar Therapeutics

> Mediar Therapeutics is a Boston clinical-stage biotech developing antibodies against signals that sustain fibrosis. Its three clinical candidates target WISP1, EphrinB2 and SMOC2 in lung, systemic sclerosis and kidney disease programs. It combines myofibroblast biology, antibody engineering and measurable biomarkers, with licensing and discovery partnerships supporting development.

- **Founded:** 2019
- **Headquarters:** Boston, United States
- **Founders:** David Lagares (Scientific co-founder), Meredith Fisher (Company co-creator; interim CEO at formation), Paul Yaworsky (Founding CSO; current Scientific Advisory Board chair)
- **Products:** MTX-463, MTX-474, MTX-439, Fibro-inflammatory antibody discovery collaboration
- **Notable:** Two programs reached Phase 1 in 2024., First WISPer Phase 2 patient dosing announced June 2025., MTX-474 entered Phase 2a; trial initiation reported January 2026.

## Products & services

- **MTX-463** — Investigational human IgG1 antibody targeting WISP1. Phase 2 WISPer trial in IPF; globally licensed to Lilly, with Mediar conducting Phase 2.
- **MTX-474** — Investigational human IgG1 antibody targeting EphrinB2. Wholly owned Phase 2a EncompaSSc program in systemic sclerosis.
- **MTX-439** — Investigational anti-SMOC2 antibody for CKD-associated fibrosis. Phase 1 includes healthy volunteers and adults with diabetic kidney disease.
- **Fibro-inflammatory antibody discovery collaboration** — Research with Ono to create antibody candidates, with Ono holding an exclusive worldwide licensing option.

## Achievements

- Two programs reached Phase 1 in 2024.
- First WISPer Phase 2 patient dosing announced June 2025.
- MTX-474 entered Phase 2a; trial initiation reported January 2026.
- Third antibody entered Phase 1; first cohorts dosed announced June 2026.
- Secured Lilly licensing and Ono discovery agreements.

## Latest updates

- **2026-08** — Signed Ono discovery collaboration and worldwide option agreement.
- **2026-06** — Announced MTX-439 Phase 1 cohort dosing and expanded kidney-disease clinical advisory expertise.
- **2026-02** — Alloy reported completion of antibody discovery collaboration.
- **2026-01** — Announced $76 million Series B and initiation of EncompaSSc Phase 2a study.

## Links

- Website: https://www.mediartx.com/
- LinkedIn: https://www.linkedin.com/company/mediar-therapeutics/

---

Profile page: https://yespress.io/mediar-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-03